Hyderabad: The Kardi Ai launch in India has introduced an AI-powered system for long-term ECG monitoring and cardiac rhythm observation. The technology combines a wearable ECG chest strap, mobile connectivity and AI-supported analysis.
The technology was launched at Daspalla Hotel in Jubilee Hills, Hyderabad, on Saturday. Dr Balakrishna, Joint Director, Ministry of Electronics and IT, Government of India, formally launched the system in the presence of healthcare professionals, company officials and other stakeholders.
Ing. Vlastimil Hrabal, Co-Founder and CEO of Kardi Ai, attended the event. Dr Ramana Jagarlamudi, Director – International Operations and Authorised Representative – India, Kardi Ai, also participated.
Dr Raghavendra Rao, Scientific Adviser and Co-Founder of Eurasia Medical Technologies LLP, joined the programme as well. Ing. Josef Hrubec, MBA, Director, CzechTrade India – Bengaluru and Regional Director, Middle East & India, CzechTrade, was also present.
Film director Krish Jagarlamudi, cardiologists, doctors and other healthcare professionals attended the launch. More than 200 people took part in the programme.
Kardi Ai focuses on longer heart rhythm observation
Hrabal said Kardi Ai had developed a digital healthcare tool to simplify long-term ECG monitoring. He explained that cardiac rhythm abnormalities can appear at unpredictable times.
As a result, a short ECG examination may not capture an intermittent abnormality. A conventional Holter test also provides continuous recording for a limited period, commonly 24 hours.
“An ECG is a snapshot of the heart,” Hrabal said. He compared that short examination with longer monitoring through a Holter device.
According to Hrabal, Kardi Ai extends the observation period for heart rhythm. This longer window may give physicians more opportunities to identify intermittent abnormalities.
He also compared the number of cardiologists in Hyderabad and the Czech Republic. Hyderabad has around 700 cardiologists, while the Czech Republic has around 1,000, he said.
Hrabal said the technology could help prevent heart strokes, save lives and prolong survival. The system is designed for use during a patient’s normal daily activities.
A patient wears a lightweight ECG chest strap during monitoring. The recorded data then moves through a mobile platform for AI-supported analysis.
Physicians can use the resulting information to review cardiac rhythm over a longer period. The system is intended to highlight potential abnormalities that may not appear during shorter monitoring sessions.
Kardi Ai reported detection rates of up to 40% with its solution. By comparison, the company cited approximately 2–5% for conventional Holter monitoring.
However, detection rates can vary according to several factors. These include the monitoring protocol, patient population and clinical definition used.
The company’s published materials also highlight longer monitoring for arrhythmias that can remain undetected during short examinations. The system therefore provides additional information for physicians during clinical evaluation.
Kardi Ai does not replace medical diagnosis or clinical decision-making. Its patient guidance says the app provides preliminary AI-supported analysis, while a physician makes the definitive diagnosis after appropriate clinical evaluation.
Kardi Ai launch brings prescription-grade medical technology
The Kardi Ai launch brings the system to India as a prescription-grade medical solution. It is not positioned as a consumer fitness device.
According to the company, the device has an MD-15 licence from the Government of India for import and sale in India. It also carries a CE mark under the European Union medical-device regulatory framework.
Kardi Ai classifies the device as an EU MDR Class IIa medical device. In addition, the company said its manufacturing and quality-management processes align with ISO 13485.
Hrubec highlighted the growing presence of Czech businesses in India during the event. He said more than 37 Czech companies operate in the country, with investments exceeding US$283 million.
Those companies have significant activity in automotive, engineering and infrastructure, he said. Hrubec also presented Kardi Ai as an example of Czech innovation entering HealthTech, artificial intelligence and digital healthcare.
“Kardi Ai is an interesting new-generation Czech company,” Hrubec said. He added that its presence reflected the wider range of Czech innovation reaching India.
CzechTrade is the Government Agency of the Czech Republic that promotes trade and facilitates cooperation between Czech and foreign businesses. Hrubec represented the agency at the Hyderabad programme.
Hyderabad-based Eurasia Medical Technologies LLP facilitated the India launch. The company serves as Kardi Ai’s Indian arm and authorised representative.
Dr Ramana Jagarlamudi and Dr Raghavendra Rao said healthcare is moving towards remote monitoring and digital health. They also discussed the growing role of AI-assisted clinical decision support.
The two officials said they were exploring the possibility of establishing manufacturing for the technology in the future. However, they did not provide a specific timeline.
The central proposition behind Kardi Ai is longer observation of cardiac rhythm. When an abnormality occurs intermittently, extended monitoring can provide physicians with more information than a short recording.
The launch brought together cardiologists, physicians, healthcare professionals and technology stakeholders. Discussions covered cardiac arrhythmias, long-term ECG monitoring, remote cardiac care and AI-supported ECG analysis.
The event carried the theme “From Signal to Insight for Healthier Lives”. The programme marked Kardi Ai’s entry into the Indian healthcare market and its expansion into long-term cardiac rhythm monitoring.
